SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 2005
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 Science Center Drive,
San Diego, California
(Address of principal executive offices)
(858) 550-7500
(Registrant’s telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02 Disclosure of Results of Operations and Financial Condition
On November 18, 2005, the registrant reported its financial results for the fiscal years ended
December 31, 2004, 2002 and 2003, preliminary results for the quarters ended March 31, 2005 and
June 30, 2005 and preliminary revenue estimates for the quarter ended September 30, 2005. A copy
of the press release issued by the registrant on November 18, 2005 concerning the foregoing results
is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements And Exhibits
| |
99.1 |
|
Press Release of the Company dated November 18, 2005 |